Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 74

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 74
---
 we or future collaborators might not have been the first to conceive and reduce to practice the inventions covered by the 
 patents or patent applications that we own, license or will own or license;                                               |

| • |     | we or future collaborators might not have been the first to file patent applications covering certain of our inventions; |

| • |     | others may independently develop similar or alternative product candidates or duplicate any of our product candidates 
 without infringing our intellectual property rights;                                                                  |

52

| • |     | it is possible that our pending patent applications will not lead to issued patents; |

| • |     | issued patents that we own or in-license may be held invalid or unenforceable as a 
 result of legal challenges by our competitors;                                     |

| • |     | issued patents that we own or in-license may not provide coverage for all aspects 
 of our product candidates in all countries;                                       |

| • |     | our competitors might conduct research and development activities in countries where we do not have patent rights and then 
 use the information learned from such activities to develop competitive products for sale in our major commercial markets; |

| • |     | ownership of our patents or patent applications may be challenged by third parties; |

| • |     | we may not develop additional proprietary intellectual property that is patentable; and |

| • |     | the patents of third parties may have an adverse effect on our business. |

Should any of these events occur, they could significantly harm our business, results of operations and prospects. If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed. We currently have rights to intellectual property, through licenses from third parties, to identify and develop certain product candidates, and we may add additional licenses in the future as we expand our product candidate pipeline. Although we have succeeded in licensing intellectual property from third-party licensors, including AbbVie, in the past, we cannot assure our stockholders that we will be able to in-licenseor acquire the rights to any potential product candidates from third parties on acceptable terms or at all. In addition, our license agreements may provide that our fields of use exclude particular fields. If we determine that rights to such fields are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain additional license rights in order to continue developing, manufacturing or marketing our product candidates. In addition, we may seek to obtain additional licenses from our licensors and, in